February 2022 - Page 3 of 4 - BioMedWire (BMW)

WednesdayFeb 09, 2022 9:30 am

Diabetes Fatalities in US Top 100,000 for Second Consecutive Year

Diabetes was the seventh-leading cause of death in the United States in 2019, claiming the lives of more than 87,000 individuals. However, recently publicized data shows that more than 100,000 individuals in the U.S. succumbed to diabetes last year. These new figures come as the National Clinical Care Commission calls for Congress to improve diabetes care and prevention, having given recommendations to stop relying solely on medical interventions. A report that was released last month urges that broader policy changes be made in an effort to contain the diabetes epidemic. These changes include expanding access to affordable housing, imposing taxes…

WednesdayFeb 09, 2022 9:00 am

Nemaura Medical Inc. (NASDAQ: NMRD) Set to Capitalize on Glucose Monitoring Sector’s Exponential Growth Rate

The blood glucose monitoring system sector is expected to grow to a value of $27.2 billion by 2026, expanding at a CAGR of 9.6% between 2021-2026 Over 420 million people around the globe currently have diabetes, with the American Diabetes Association recommending that all adults screen for the condition every three years Nemaura Medical has sought to capitalize on the blood glucose monitoring sector’s phenomenal growth rate through the launch of its proprietary body worn continuous glucose sensor in both the diabetes sector and consumer healthcare sector. The company’s flagship sugarBEAT(R) device provides diabetic and pre-diabetic patients with the ability…

TuesdayFeb 08, 2022 12:05 pm

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Marks a Major Step in Seamless Phase 2/3 Smoking Cessation Clinical Trial; Partners with Combat Stress to Treat PTSD among Veterans

Mydecine has summitted a pre-IND briefing package to the FDA in readiness for its phase 2/3 smoking cessation trial scheduled for Q2 2022 The study will be led by Dr. Matthew Johnson, with the placebo-controlled research being conducted at Johns Hopkins University Mydecine also announced its partnership with Combat Stress to use psilocybin in a psychoactive-assisted psychotherapy PTSD treatment program for veterans Combat Stress will also be one of several sites for the company’s upcoming clinical trials set to launch later in the year Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) plans to launch its seamless phase 2/3 smoking cessation…

TuesdayFeb 08, 2022 9:30 am

COVID-19 Stress May Cause Onset of PTSD

New research has discovered that traumatic stress associated with the coronavirus may be used to predict post-traumatic stress disorder. The researchers found a link between PTSD and COVID traumatic stress, noting that it was stronger in people who had repeatedly experienced past trauma. In their report, the researchers noted that their findings were true across almost all racial groups, excluding Asian Americans. The lead author of the study, Professor Jeff Ashby, has specialized in counseling and psychological services. He stated that despite many individuals being insulated from economic hardship and deaths associated with the pandemic, there was a universal experience…

MondayFeb 07, 2022 9:30 am

Combination of Two Existing Therapies May Help Treat Pediatric Brain Cancer

Researchers at the Catholic University of the Sacred Heart medical school in Italy and Johns Hopkins Medicine in Boston have found new evidence suggesting that a prospective copper therapy can be used to help save children suffering from medulloblastoma. Medulloblastoma is a rapidly growing central nervous system cancer that originates in the spinal cord or brain. This cancer is the most common pediatric brain malignancy and mainly seen in children aged 10 and below. Figures show that about 500 cases of this particular cancer are diagnosed yearly. The rate of survival for children suffering from medulloblastoma when the disease hasn’t…

FridayFeb 04, 2022 9:30 am

Depression, PTSD and Addiction Levels Continue to Rise as Omicron Cases Increase

Data from the Mental Health Index shows that mental health in America has hit an all-time low as the COVID-19 pandemic rages on. The rates of addiction, depression and post-traumatic stress disorder are soaring, as cases of omicron increase. Currently, one in four workers in America has screened positive for PTSD. This is a 54% increase in the last three months and a 135% increase when compared to the levels recorded prior to the pandemic. Rates of depression have also grown by 86% since fall, which is 63% higher than prepandemic levels. A significant increase in addiction in men has…

ThursdayFeb 03, 2022 10:53 am

Study Suggests That Chemotherapy Administration Time May Impact Effectiveness

A new study has found that chemotherapy that is administered at night can target brain tumors better, as observed in mouse models, in comparison to day-time administered chemotherapy. The researchers hypothesize that the blood-brain barrier may allow the cancer treatment to pass through more easily at night. The blood-brain barrier helps prevent foreign substances such as germs and toxins from accessing the brain. However, it also makes it harder to treat tumors as it blocks chemotherapy from entering the brain. Currently, individuals on chemotherapy usually receive their treatment during the day. The team of researchers carrying out the study is…

ThursdayFeb 03, 2022 10:00 am

InMed Pharmaceuticals Inc. (NASDAQ: INM) Strengthens Leading Role in Rare Cannabinoid Market Following New Product Launch, Key Acquisition

Cannabicitran is the first of four new rare cannabinoids InMed is planning to launch in the first half of the year to meet growing inbound demand The launch demonstrates InMed’s ability to produce rare cannabinoids at scale, something only very few companies have achieved BayMedica acquisition, other key achievements in 2021, are positioning the company as a leading supplier of rare cannabinoids in the health and wellness sector A leader in the research, development, manufacturing and commercialization of rare cannabinoids, InMed Pharmaceuticals (NASDAQ: INM) has begun the new year from a more prominent position in the market, following key acquisitions…

WednesdayFeb 02, 2022 12:40 pm

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Clinical LOI to Further Use of Psychedelic Therapeutics in Treating Mental Illnesses

Canadian-based mental health treatment-focused biotechnology company Mydecine Innovations Group has been advancing research on the use and improvement of compounds found in nature, particularly the psychedelic psilocybin compound Mydecine recently announced an LOI with The Newly Institute to use Mydecine’s psilocybin and MDMA for treatment at The Newly’s mental health clinics nationwide The LOI is the first collaboration under Mydecine’s SASSP program, which will provide psychedelic drug products and related services to physicians, clinics and hospitals in Canada for psychotherapy Health Canada announced earlier this month that the government has amended its medicinal regulations to allow psilocybin and MDMA prescriptions…

WednesdayFeb 02, 2022 11:18 am

Lung Cancer Not Just a Smoker’s Problem

February 4 is World Cancer Day, which makes this an ideal time to discuss smoking and lung cancer. Globally, lung cancer is one of the most common causes of cancer death, with estimates from the World Health Organization (“WHO”) showing that roughly 90% of lung cancer cases can be prevented by eliminating the use of tobacco. Individuals who smoke have a high risk of developing this disease, with studies also linking smokeless tobacco to lung cancer. Did you know, however, that lung cancer can also develop in individuals who don’t use tobacco? Dr. Aaron Mansfield, an oncologist who specializes in…